Quintrio
Home

SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC

Ardent Health, Inc.

ARDT

Ardent Health Inc is a provider of healthcare in growing mid-sized urban communities across the U.S and operating in eight growing mid-sized urban markets across six states Texas, Oklahoma, New Mexico, New Jersey, Idaho, and Kansas. The main focus on people and investments in services and technologies.

Last trade $17.84
Day change -$0.26 (-1.44%)
Day range $17.78 – $18.34
Volume 227,366
Market cap $2.55B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$2.55B
Price / earnings
17.45×
Price / book
1.83×
Price / sales
0.4×
EV / sales
0.45×
EV / EBITDA
5.66×

Profitability

Earnings per share
$1.04
Return on assets
2.73%
Return on equity
10.47%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.79×
Current ratio
2.26×
Quick ratio
2.14×
Cash ratio
0.8×

Cash flow

Price / cash flow
5.29×
Price / free cash flow
9.04×
Free cash flow
$282.3M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ARDT, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$1.62B$1.62B$1.6B$1.61B$1.58B$1.65B$1.5B$1.61B
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$1.62B$1.62B$1.6B$1.61B$1.58B$1.65B$1.5B$1.61B
Selling, general and administrative$975.75M$1B$978.5M$961.08M$982.05M$968.71M$938.51M$940.27M
Research and development$0$0$0$0$0$0$0$0
Total operating expenses$1.53B$1.57B$1.52B$1.5B$1.56B$1.51B$1.41B$1.45B
Operating income$95.34M$55.77M$86.8M$104.75M$16.46M$136.72M$88.37M$157.57M
Interest expense-$15.32M-$12.57M-$12.21M-$12.38M-$13.91M-$14.73M-$14.18M-$13.53M
Income before taxes$81.03M$43.2M$74.59M$92.37M-$2.2M$121.99M$74.2M$167.25M
Income taxes$17.64M$8.51M$16.1M$18.11M-$3.41M$26.29M$15.23M$26.36M
Net income$63.39M$34.69M$58.49M$74.26M$1.21M$95.7M$58.97M$140.89M
Net income attributable to common shareholders$44.52M$16.9M$39.85M$44.96M-$23.48M$72.95M$41.38M$114.2M
EBITDA$136.4M$97.11M$129.79M$145.79M$55.61M$176.03M$124.58M$195.43M
Basic earnings per share$0.32$0.12$0.28$0.32-$0.17$0.52$0.30$0.81
Diluted earnings per share$0.31$0.12$0.28$0.32-$0.17$0.52$0.29$0.81

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Ardent Health, Inc. (ARDT) Beats Q3 Earnings and Revenue Estimates

Ardent Health, Inc. (ARDT) reported Q3 2026 earnings of $0.31 per share, beating consensus estimates of $0.24, with revenues of $1.62 billion slightly exceeding expectations. However, the company received a Zacks Rank #3 (Hold) rating due to mixed estimate revision trends. The stock has outperformed the S&P 500 by 22% year-to-date, but future performance will depend on management guidance and earnings estimate revisions.

Zacks Investment Research

Is the Options Market Predicting a Spike in Ardent Health Stock?

Ardent Health, Inc. (ARDT) is drawing attention from options traders due to high implied volatility in its January 15, 2026 $2.50 call options, suggesting market expectations for significant price movement. The company holds a Zacks Rank #3 (Hold) rating in the Medical Services Industry, with analysts slightly raising estimates for the current quarter from 23 to 24 cents per share over the last 30 days.

The Motley Fool

Is Ardent Health Stock a Buy After a Director Purchased More Than 11,000 Shares?

Ardent Health director Robert DeMichiei purchased 11,260 shares on June 5, 2026, for approximately $98,000 at $8.73 per share, increasing his holdings by 46%. This marks the first open-market insider buy in a year for the hospital operator, with the CFO also purchasing shares the same day. The purchases signal insider confidence despite the stock's 27.51% decline over the past year.

GlobeNewswire Inc.

ARDENT HEALTH FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Ardent Health, Inc. Stockholders to Contact the Firm Before March 9th Regarding Their Rights

A class action lawsuit has been filed against Ardent Health, Inc. for allegedly reporting inflated accounts receivable and delaying loss recognition on uncollectable accounts during the class period of July 18, 2024 to November 12, 2025. The company revealed a $43 million revenue decrease in Q3 2025 after transitioning to a new accounting system, causing the stock to plummet 34% from $14.05 to $9.30 per share. Investors have until March 9, 2026 to apply as lead plaintiff.

GlobeNewswire Inc.

Bronstein, Gewirtz & Grossman LLC Urges Ardent Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Ardent Health, Inc. alleging that the company made materially false and misleading statements regarding its Q3 2025 revenue and 2025 EBITDA guidance. The complaint claims revenue was overstated due to inadequate accounts receivable assessments following a new accounting system implementation, and EBITDA guidance was overstated by approximately $57.5 million (9.6%) due to industry-wide cost pressures and payer denials. Investors who purchased Ardent securities between July 18, 2024 and November 12, 2025 are encouraged to join the lawsuit.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.